Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Nov;64(Suppl 4):iv65–iv69. doi: 10.1136/ard.2005.042440

Health economics: implications for novel antirheumatic therapies

A Kavanaugh
PMCID: PMC1766909  PMID: 16239392

Abstract

This paper discusses the pharmacoeconomics issues relating to the use of the newer therapies for rheumatoid arthritis (RA), namely the tumour necrosis factor (TNF) inhibitors. Results of recent studies have provided some evidence regarding the cost effectiveness of these agents. However, as the use of TNF inhibitors evolves—including their use in other systemic inflammatory diseases—this will be influenced by several factors including treatment of patients with early RA, longer term treatment, problems related to toxicity, quality of life, productivity, and market forces. Thus, pharmacoeconomic considerations are likely to remain a central factor in the use of novel therapies in rheumatology, and awareness about these will aid clinicians to select the most favourable therapies for their patients with arthritis.

Full Text

The Full Text of this article is available as a PDF (66.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birrell F. N., Hassell A. B., Jones P. W., Dawes P. T. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values? A cross-sectional study. Clin Rheumatol. 2000;19(3):195–199. doi: 10.1007/s100670050155. [DOI] [PubMed] [Google Scholar]
  2. Brennan A., Bansback N., Reynolds A., Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2003 Jul 30;43(1):62–72. doi: 10.1093/rheumatology/keg451. [DOI] [PubMed] [Google Scholar]
  3. Choi H. K., Seeger J. D., Kuntz K. M. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum. 2000 Oct;43(10):2316–2327. doi: 10.1002/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  4. Cooper N. J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000 Jan;39(1):28–33. doi: 10.1093/rheumatology/39.1.28. [DOI] [PubMed] [Google Scholar]
  5. Dunlop Dorothy D., Manheim Larry M., Yelin Edward H., Song Jing, Chang Rowland W. The costs of arthritis. Arthritis Rheum. 2003 Feb 15;49(1):101–113. doi: 10.1002/art.10913. [DOI] [PubMed] [Google Scholar]
  6. Fex E., Larsson B. M., Nived K., Eberhardt K. Effect of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol. 1998 Jan;25(1):44–50. [PubMed] [Google Scholar]
  7. Fries J. F. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I86–I89. doi: 10.1136/ard.58.2008.i86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gabriel S. E., Crowson C. S., Campion M. E., O'Fallon W. M. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol. 1997 Jan;24(1):43–48. [PubMed] [Google Scholar]
  9. Gabriel S. E., Crowson C. S., O'Fallon W. M. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol. 1999 Dec;26(12):2529–2533. [PubMed] [Google Scholar]
  10. Gabriel S., Tugwell P., O'Brien B., Yelin E., Drummond M., Ruff B., Brooks P., Bombardier C., Boers M. Report of the OMERACT task force on economic evaluation. Outcome Measures in Rheumatology. J Rheumatol. 1999 Jan;26(1):203–206. [PubMed] [Google Scholar]
  11. Gabriel Sherine E., Crowson Cynthia S., Kremers Hilal Maradit, Doran Michele F., Turesson Carl, O'Fallon W. Michael, Matteson Eric L. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003 Jan;48(1):54–58. doi: 10.1002/art.10705. [DOI] [PubMed] [Google Scholar]
  12. Genovese Mark C., Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. doi: 10.1002/art.10308. [DOI] [PubMed] [Google Scholar]
  13. Guillemin F. The value of utility: assumptions underlying preferences and quality adjusted life years. J Rheumatol. 1999 Sep;26(9):1861–1863. [PubMed] [Google Scholar]
  14. Hallert E., Husberg M., Jonsson D., Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA project). Rheumatology (Oxford) 2004 Jul 27;43(11):1374–1382. doi: 10.1093/rheumatology/keh324. [DOI] [PubMed] [Google Scholar]
  15. Hurst N. P., Forbes J. Does economic evaluation have anything to offer the rheumatologist? Rheumatology (Oxford) 1999 Jan;38(1):2–5. doi: 10.1093/rheumatology/38.1.2. [DOI] [PubMed] [Google Scholar]
  16. Jäntti J., Aho K., Kaarela K., Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. Rheumatology (Oxford) 1999 Nov;38(11):1138–1141. doi: 10.1093/rheumatology/38.11.1138. [DOI] [PubMed] [Google Scholar]
  17. Kavanaugh A., Heudebert G., Cush J., Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum. 1996 Apr;25(5):297–307. doi: 10.1016/s0049-0172(96)80016-3. [DOI] [PubMed] [Google Scholar]
  18. Kavanaugh Arthur, Cohen Stanley, Cush John J. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. J Rheumatol. 2004 Oct;31(10):1881–1884. [PubMed] [Google Scholar]
  19. Kavanaugh Arthur, Han Chenglong, Bala Mohan. Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. J Rheumatol. 2004 May;31(5):849–855. [PubMed] [Google Scholar]
  20. Keystone Edward C., Kavanaugh Arthur F., Sharp John T., Tannenbaum Hyman, Hua Ye, Teoh Leah S., Fischkoff Steven A., Chartash Elliot K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May;50(5):1400–1411. doi: 10.1002/art.20217. [DOI] [PubMed] [Google Scholar]
  21. Klareskog Lars, van der Heijde Désirée, de Jager Julien P., Gough Andrew, Kalden Joachim, Malaise Michel, Martín Mola Emilio, Pavelka Karel, Sany Jacques, Settas Lucas. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004 Feb 28;363(9410):675–681. doi: 10.1016/S0140-6736(04)15640-7. [DOI] [PubMed] [Google Scholar]
  22. Kobelt G., Andlin-Sobocki P., Brophy S., Jönsson L., Calin A., Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004 Jun 29;43(9):1158–1166. doi: 10.1093/rheumatology/keh271. [DOI] [PubMed] [Google Scholar]
  23. Kobelt G., Eberhardt K., Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis. 2004 Jan;63(1):4–10. doi: 10.1136/ard.2003.010629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kobelt G., Eberhardt K., Jönsson L., Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999 Feb;42(2):347–356. doi: 10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  25. Kobelt G., Jönsson L., Young A., Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003 Feb;42(2):326–335. doi: 10.1093/rheumatology/keg107. [DOI] [PubMed] [Google Scholar]
  26. Kobelt Gisela, Jönsson Linus, Lindgren Peter, Young Adam, Eberhardt Kerstin. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 2002 Sep;46(9):2310–2319. doi: 10.1002/art.10471. [DOI] [PubMed] [Google Scholar]
  27. Lajas Cristina, Abasolo Lydia, Bellajdel Boutayeb, Hernández-García César, Carmona Loreto, Vargas Emilio, Lázaro Pablo, Jover Juan A. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 2003 Feb 15;49(1):64–70. doi: 10.1002/art.10905. [DOI] [PubMed] [Google Scholar]
  28. Lambert C. M. Medical therapy for rheumatoid arthritis--value for money? Rheumatology (Oxford) 2001 Sep;40(9):961–964. doi: 10.1093/rheumatology/40.9.961. [DOI] [PubMed] [Google Scholar]
  29. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  30. Maetzel A., Li L. C., Pencharz J., Tomlinson G., Bombardier C., Community Hypertension and Arthritis Project Study Team The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004 Apr;63(4):395–401. doi: 10.1136/ard.2003.006031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Maini R. N., Breedveld F. C., Kalden J. R., Smolen J. S., Furst D., Weisman M. H., St Clair E. W., Keenan G. F., van der Heijde D., Marsters P. A. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004 Apr;50(4):1051–1065. doi: 10.1002/art.20159. [DOI] [PubMed] [Google Scholar]
  32. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  33. Michaud Kaleb, Messer Jodi, Choi Hyon K., Wolfe Frederick. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003 Oct;48(10):2750–2762. doi: 10.1002/art.11439. [DOI] [PubMed] [Google Scholar]
  34. Pincus T., Brooks R. H., Callahan L. F. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med. 1994 Jan 1;120(1):26–34. doi: 10.7326/0003-4819-120-1-199401010-00005. [DOI] [PubMed] [Google Scholar]
  35. Pincus T., Kavanaugh A., Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S2–11. [PubMed] [Google Scholar]
  36. Pincus T., Sokka T., Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 2001 Jun;44(6):1234–1236. doi: 10.1002/1529-0131(200106)44:6<1234::AID-ART213>3.0.CO;2-R. [DOI] [PubMed] [Google Scholar]
  37. Quinn Mark A., Conaghan Philip G., O'Connor Philip J., Karim Zunaid, Greenstein Adam, Brown Andrew, Brown Clare, Fraser Alexander, Jarret Stephen, Emery Paul. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005 Jan;52(1):27–35. doi: 10.1002/art.20712. [DOI] [PubMed] [Google Scholar]
  38. Rat Anne-Christine, Boissier Marie-Christophe. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004 Nov;71(6):518–524. doi: 10.1016/j.jbspin.2004.01.003. [DOI] [PubMed] [Google Scholar]
  39. Ruff B. OMERACT: economic evaluations and health policy. J Rheumatol. 1999 Oct;26(10):2076–2077. [PubMed] [Google Scholar]
  40. Sokka Tuulikki, Krishnan Eswar, Häkkinen Arja, Hannonen Pekka. Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum. 2003 Jan;48(1):59–63. doi: 10.1002/art.10731. [DOI] [PubMed] [Google Scholar]
  41. Verstappen S. M. M., Bijlsma J. W. J., Verkleij H., Buskens E., Blaauw A. A. M., ter Borg E. J., Jacobs J. W. G., Utrecht Rheumatoid Arthritis Cohort Study Group Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum. 2004 Jun 15;51(3):488–497. doi: 10.1002/art.20419. [DOI] [PubMed] [Google Scholar]
  42. Weinblatt M. E., Kremer J. M., Bankhurst A. D., Bulpitt K. J., Fleischmann R. M., Fox R. I., Jackson C. G., Lange M., Burge D. J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28;340(4):253–259. doi: 10.1056/NEJM199901283400401. [DOI] [PubMed] [Google Scholar]
  43. Weinblatt Michael E., Keystone Edward C., Furst Daniel E., Moreland Larry W., Weisman Michael H., Birbara Charles A., Teoh Leah A., Fischkoff Steven A., Chartash Elliot K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35–45. doi: 10.1002/art.10697. [DOI] [PubMed] [Google Scholar]
  44. Weisman Michael H., Gano Anacleto D., Jr, Gabriel Sherine E., Hochberg Marc C., Kavanaugh Arthur, Ofman Joshua J., Prashker Mark, Suarez-Almazor Maria E., Yelin Edward, Nakelsky Shoshanna D. Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. J Rheumatol. 2003 Aug;30(8):1739–1747. [PubMed] [Google Scholar]
  45. Wiles N. J., Scott D. G., Barrett E. M., Merry P., Arie E., Gaffney K., Silman A. J., Symmons D. P. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis. 2001 Oct;60(10):956–961. doi: 10.1136/ard.60.10.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wolfe F., Michaud K., Pincus T. Do rheumatology cost-effectiveness analyses make sense? Rheumatology (Oxford) 2003 Oct 1;43(1):4–6. doi: 10.1093/rheumatology/keh034. [DOI] [PubMed] [Google Scholar]
  47. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med. 1997 Dec 29;103(6A):12S–18S. doi: 10.1016/s0002-9343(97)90003-6. [DOI] [PubMed] [Google Scholar]
  48. Wong J. B. Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S65–S70. [PubMed] [Google Scholar]
  49. Wong John B., Singh Gurkirpal, Kavanaugh Arthur. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med. 2002 Oct 1;113(5):400–408. doi: 10.1016/s0002-9343(02)01243-3. [DOI] [PubMed] [Google Scholar]
  50. Yelin E., Wanke L. A. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999 Jun;42(6):1209–1218. doi: 10.1002/1529-0131(199906)42:6<1209::AID-ANR18>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  51. Yelin Edward, Trupin Laura, Katz Patricia, Lubeck Deborah, Rush Stephanie, Wanke Lee. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum. 2003 Nov;48(11):3046–3054. doi: 10.1002/art.11285. [DOI] [PubMed] [Google Scholar]
  52. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]
  53. van de Putte L. B. A., Rau R., Breedveld F. C., Kalden J. R., Malaise M. G., van Riel P. L. C. M., Schattenkirchner M., Emery P., Burmester G. R., Zeidler H. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003 Dec;62(12):1168–1177. doi: 10.1136/ard.2003.009563. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES